U.S. RESEARCH ROUNDUP-Carmax, Mindbody, Neurometrix

Marine Products

26/12/2018 12:16

Dec 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Carmax, Mindbody and Neurometrix, on Wednesday. 
    
    HIGHLIGHTS
     * Capricor Therapeutics Inc  CAPR.O : Maxim cuts rating to hold from buy
     * Carmax Inc  KMX.N : Guggenheim raises to buy from neutral
     * Corbus Pharmaceuticals Holdings  CRBP.O : H.C. Wainwright initiates with buy, $24 PT
     * Mindbody Inc  MB.O : D.A. Davidson cuts rating to neutral from buy    
     * Neurometrix Inc  NURO.O : H.C.Wainwright starts with buy; price target $5     
 Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday.
Stock entries are in alphabetical order. 
    
    
     * Capricor Therapeutics Inc  CAPR.O : Maxim cuts rating to hold from buy
     * Carmax Inc  KMX.N : Guggenheim raises to buy from neutral
     * Corbus Pharmaceuticals Holdings  CRBP.O : H.C. Wainwright initiates with buy, $24 PT
     * Corenergy Infrastructure Trust  CORR.N : D.A. Davidson cuts price target by $5 to $40
     * Marine Products Corp  MPX.N : B.Riley FBR raises to neutral from sell
     * Mindbody Inc  MB.O : Craig Hallum raises price target to $36.50 from $32
     * Mindbody Inc  MB.O : D.A. Davidson cuts rating to neutral from buy 
     * Mindbody Inc  MB.O : D.A. Davidson raises price target to $36.50 from $33
     * Neurometrix Inc  NURO.O : H.C.Wainwright starts with buy; price target $5
     * Norwegian Cruise Line Holdings Ltd  NCLH.N : Wedbush removes Co from its best ideas list
 
 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))